Core Viewpoint - The forum focused on "Investment Logic and Value Creation Driven by New Quality Productivity," emphasizing opportunities in hard technology sectors, technological innovation, and the integration of capital and industry [1]. Group 1: Key Themes and Discussions - The "New Quality Productivity Investment Forum" was successfully held, providing a professional platform for deep communication and collaboration in the industry [1]. - Liu Haofei, the founding partner of Shengjing Jiacheng, highlighted that sectors such as AI, embodied intelligence, low-altitude economy, and technology going abroad could create opportunities worth trillions [5]. - The investment strategy proposed by Liu involves a "three horizontal and multiple vertical" approach, focusing on large enterprise incubation, AI result-oriented RaaS models, and supporting entrepreneurs in going abroad [5]. Group 2: Roundtable Discussions - A roundtable on "Value Creation in the New Quality Productivity Era" featured discussions on industry innovation and how startups can cope with internal competition, led by Wang Meng from Junshan Mother Fund [8]. - Another discussion on "New Opportunities in Technology-Driven Consumption" explored how to seize historical opportunities in technology-driven consumption and the relationship between future and traditional industries, moderated by Yao Fengjiao from Bailian Zhigao Capital [10]. - The session on "Healthcare and Wellness Across Cycles" addressed strategies for capitalizing on the recovery in the healthcare sector and opportunities in AI healthcare, moderated by Yi Lin from Defu Capital [14]. Group 3: Industry Trends - Si Tingyou, president of BC Asset Management, discussed trends in China's innovative pharmaceuticals, noting that recent collaborations between Chinese innovative drug companies and international pharmaceutical giants indicate recognition of China's R&D capabilities [12]. - The future focus for Chinese innovative drugs should be on global innovation, with the Hong Kong market expected to see long-term foreign capital inflows [12].

Core Insights - The second Xiong'an Future City Scenario Competition finals commenced on June 9, featuring 11 categories including smart agriculture, aerospace information, robotics, fintech, vertical large models, healthcare, green low-carbon initiatives, cybersecurity, intelligent networking, emergency response, and low-altitude transportation [1] - A total of 981 teams with 1,191 projects advanced to the finals, which will conclude by the end of June [1] - Xiong'an New Area has introduced measures to promote the transformation and application of competition results, aiming to attract innovative tech enterprises and enhance high-quality development [1]

Report Summary 1. Report Industry Investment Rating There is no information provided regarding the industry investment rating in the given content. 2. Report's Core View - The report focuses on the in - depth research of Anxu Bio, a biotech company in the medical device industry. It highlights the company's comprehensive strength, including its strong R & D capabilities, diverse product lines, and strategic layout for future development. Anxu Bio aims to become a leading enterprise in the international in - vitro diagnostic industry through continuous innovation and market expansion [23][24]. 3. Summary by Related Catalogs 3.1. Research Basic Situation - The research object is Anxu Bio, belonging to the medical device industry. The reception time was on May 20, 2025. The listed company's reception staff included the company's chairman and general manager Ling Shisheng, board secretary Han Jun, financial controller Kang Min, and independent director Zhang Guobiao [16]. 3.2. Detailed Research Institutions - The relevant personnel participated in the "2024 Annual Report and 2025 First - Quarter Performance Briefing" [19]. 3.3. Research Institution Proportion There is no specific information provided about the research institution proportion in the given text. 3.4. Main Content Data 3.4.1. Company Basic Situation Introduction - Anxu Bio was founded in 2008 and went public on the Science and Technology Innovation Board in November 2021. It is a high - tech biotech enterprise integrating R & D, production, and sales of in - vitro diagnostic reagents, POCT instruments, and biological raw materials. It has achieved an integrated industrial chain layout from upstream core biological raw materials to diagnostic reagents and instruments [23]. - The company has eight major fields of POCT reagents and related supporting instruments, covering drug testing, infectious disease testing, etc., and its products are sold in more than 150 countries and regions. It also actively strategically layouts in the pharmaceutical field, such as third - party medical testing laboratories, pet health management, and family health management [23][24]. - In the future, the company will continue to increase investment in R & D and production of biological raw materials, improve the performance of POCT reagents and instruments, and focus on both international and domestic markets to become a leading enterprise in the international in - vitro diagnostic industry [24]. 3.4.2. Q&A Session Main Content - **Financial Performance**: In 2024, the company's operating income was 540.6985 million yuan, net profit attributable to the parent company was 192.2953 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 37.8979 million yuan. In the first quarter of 2025, the operating income was 115.2965 million yuan, net profit attributable to the parent company was 34.0296 million yuan, and net profit attributable to the parent company after deducting non - recurring gains and losses was 22.7603 million yuan [25]. - **R & D Breakthroughs and Advantages**: The company has built nine technology platforms, forming a trinity industrial chain layout of raw materials, reagents, and instruments. In 2024, it added 44 authorized patents (including 13 invention patents), with a total of 305 authorized patents, and added 606 international and domestic certifications, with a total of 1580 certifications, including EU CE and US FDA [25]. - **Business Expansion**: The company promotes the iteration of core products, builds a diversified product matrix, and explores performance growth potential in fields such as pet health management, family health management, and medical testing laboratories, advancing the Anxu Bio medical and health ecosystem strategy [26]. - **Future Profit Growth Drivers**: The company will focus on technological innovation, increase R & D investment, explore frontier technology fields, continue to expand overseas markets while increasing efforts in the domestic market, and consider expanding medical and health - related business through cooperation, investment, or mergers and acquisitions [26]. - **GluMate App**: With the rising global prevalence of chronic diseases, GluMate is launched to improve the health management of chronic disease patients. It aims to transform from single - detection to full - cycle service and build a chronic disease monitoring product system centered on GluMate, providing intelligent and personalized chronic disease management solutions [27]. - **2024 Dividend Policy**: In 2024, the company plans to distribute a cash dividend of 8 yuan per 10 shares (tax - included) to all shareholders, with a total cash dividend of 152.499366 million yuan (including the interim dividend), accounting for 79.30% of the net profit attributable to listed company shareholders in the 2024 consolidated statements [28]. - **Market Expansion Measures and Achievements**: The company adheres to the "international + domestic" dual - wheel drive strategy. Overseas, its products are sold in more than 150 countries and regions, and it participates in well - known exhibitions to enhance brand influence. Domestically, it has obtained new product registration certificates and promoted brand sales through online and offline channels. It has also established subsidiaries in Singapore, the United States, and Europe to optimize the global marketing network [28][29].